FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116865296> ?p ?o ?g. }

• W2116865296 endingPage "2" @default.
• W2116865296 startingPage "2" @default.
• W2116865296 abstract "The lupus-associated (La)-specific murine monoclonal antibody DAB4 (APOMAB®) specifically binds dead cancer cells. Using DAB4, we examined La expression in human lung cancer samples to assess its suitability as a cancer-selective therapeutic target. We evaluated the safety and effectiveness of radioimmunotherapy (RIT) using DAB4 radiolabeled with Lutetium-177 (177Lu) in the murine Lewis Lung (LL2) carcinoma model, and determined whether combining RIT with DNA-damaging cisplatin-based chemotherapy, a PARP inhibitor (PARPi), or both alters treatment responses. The expression of La mRNA in human lung cancer samples was analysed using the online database Oncomine, and the protein expression of La was examined using a TissueFocus Cancer Survey Tissue Microarray. The binding of DAB4 to cisplatin-treated LL2 cells was assessed in vitro. LL2 tumour-bearing mice were administered escalating doses of 177Lu-DAB4 alone or in combination with chemotherapy, and tumour growth and survival measured. Biodistribution analysis was used to determine tissue uptake of 177Lu-DAB4 or its isotype control (177Lu-Sal5), when delivered alone or after chemotherapy. PARPi (rucaparib; AG-014699) was combined with chemotherapy and the effects of combined treatment on tumour growth, tumour cell DNA damage and death, and intratumoural DAB4 binding were also analysed. The effect of the triple combination of PARPi, chemotherapy and 177Lu-DAB4 on tumour growth and survival of LL2 tumour-bearing mice was tested. La was over-expressed at both mRNA and protein levels in surgical specimens of human lung cancer and the over-expression of La mRNA conferred a poorer prognosis. DAB4 bound specifically to cisplatin-induced dead LL2 cells in vitro. An anti-tumour dose response was observed when escalating doses of 177Lu-DAB4 were delivered in vivo, with supra-additive responses observed when chemotherapy was combined with 177Lu-DAB4. Combining PARPi with chemotherapy was more effective than chemotherapy alone with increased tumour cell DNA damage and death, and intratumoural DAB4 binding. The combination of PARPi, chemotherapy and 177Lu-DAB4 was well-tolerated and maximised tumour growth delay. The La antigen represents a dead cancer cell-specific target in lung cancer, and DAB4 specifically targeted tumour tissue in vivo, particularly after chemotherapy. Tumour uptake of DAB4 increased further after the combination of PARPi and chemotherapy, which generated new dead tumour cell-binding targets. Consequently, combining 177Lu-DAB4 with PARPi and chemotherapy produced the greatest anti-tumour response. Therefore, the triple combination of PARPi, chemotherapy and RIT may have broad clinical utility." @default.
• W2116865296 created "2016-06-24" @default.
• W2116865296 creator A5009918504 @default.
• W2116865296 creator A5021075431 @default.
• W2116865296 creator A5023578908 @default.
• W2116865296 creator A5036264210 @default.
• W2116865296 creator A5060655524 @default.
• W2116865296 creator A5081437480 @default.
• W2116865296 creator A5083049134 @default.
• W2116865296 creator A5084689064 @default.
• W2116865296 date "2014-01-01" @default.
• W2116865296 modified "2023-10-11" @default.
• W2116865296 title "The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®" @default.
• W2116865296 cites W1986848782 @default.
• W2116865296 cites W2005966376 @default.
• W2116865296 cites W2006344771 @default.
• W2116865296 cites W2031020334 @default.
• W2116865296 cites W2035064970 @default.
• W2116865296 cites W2044545697 @default.
• W2116865296 cites W2044863150 @default.
• W2116865296 cites W2046759180 @default.
• W2116865296 cites W2047004048 @default.
• W2116865296 cites W2051912646 @default.
• W2116865296 cites W2052020365 @default.
• W2116865296 cites W2059971436 @default.
• W2116865296 cites W2061425474 @default.
• W2116865296 cites W2065396079 @default.
• W2116865296 cites W2075513808 @default.
• W2116865296 cites W2094185359 @default.
• W2116865296 cites W2097583984 @default.
• W2116865296 cites W2097984332 @default.
• W2116865296 cites W2100457669 @default.
• W2116865296 cites W2104504726 @default.
• W2116865296 cites W2106787323 @default.
• W2116865296 cites W2109860478 @default.
• W2116865296 cites W2115768394 @default.
• W2116865296 cites W2116012295 @default.
• W2116865296 cites W2124092811 @default.
• W2116865296 cites W2127919472 @default.
• W2116865296 cites W2129460554 @default.
• W2116865296 cites W2132165198 @default.
• W2116865296 cites W2139761471 @default.
• W2116865296 cites W2140010849 @default.
• W2116865296 cites W2143107321 @default.
• W2116865296 cites W2144085357 @default.
• W2116865296 cites W2144107170 @default.
• W2116865296 cites W2149605504 @default.
• W2116865296 cites W2165565033 @default.
• W2116865296 doi "https://doi.org/10.1186/2191-219x-4-2" @default.
• W2116865296 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3882100" @default.
• W2116865296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24387284" @default.
• W2116865296 hasPublicationYear "2014" @default.
• W2116865296 type Work @default.
• W2116865296 sameAs 2116865296 @default.
• W2116865296 citedByCount "22" @default.
• W2116865296 countsByYear W21168652962014 @default.
• W2116865296 countsByYear W21168652962015 @default.
• W2116865296 countsByYear W21168652962018 @default.
• W2116865296 countsByYear W21168652962019 @default.
• W2116865296 countsByYear W21168652962020 @default.
• W2116865296 countsByYear W21168652962021 @default.
• W2116865296 countsByYear W21168652962022 @default.
• W2116865296 crossrefType "journal-article" @default.
• W2116865296 hasAuthorship W2116865296A5009918504 @default.
• W2116865296 hasAuthorship W2116865296A5021075431 @default.
• W2116865296 hasAuthorship W2116865296A5023578908 @default.
• W2116865296 hasAuthorship W2116865296A5036264210 @default.
• W2116865296 hasAuthorship W2116865296A5060655524 @default.
• W2116865296 hasAuthorship W2116865296A5081437480 @default.
• W2116865296 hasAuthorship W2116865296A5083049134 @default.
• W2116865296 hasAuthorship W2116865296A5084689064 @default.
• W2116865296 hasBestOaLocation W21168652961 @default.
• W2116865296 hasConcept C121608353 @default.
• W2116865296 hasConcept C126322002 @default.
• W2116865296 hasConcept C142724271 @default.
• W2116865296 hasConcept C159654299 @default.
• W2116865296 hasConcept C203014093 @default.
• W2116865296 hasConcept C2776146153 @default.
• W2116865296 hasConcept C2776256026 @default.
• W2116865296 hasConcept C2776694085 @default.
• W2116865296 hasConcept C2777847059 @default.
• W2116865296 hasConcept C2778239845 @default.
• W2116865296 hasConcept C2779013556 @default.
• W2116865296 hasConcept C502942594 @default.
• W2116865296 hasConcept C542903549 @default.
• W2116865296 hasConcept C71924100 @default.
• W2116865296 hasConcept C96232424 @default.
• W2116865296 hasConceptScore W2116865296C121608353 @default.
• W2116865296 hasConceptScore W2116865296C126322002 @default.
• W2116865296 hasConceptScore W2116865296C142724271 @default.
• W2116865296 hasConceptScore W2116865296C159654299 @default.
• W2116865296 hasConceptScore W2116865296C203014093 @default.
• W2116865296 hasConceptScore W2116865296C2776146153 @default.
• W2116865296 hasConceptScore W2116865296C2776256026 @default.
• W2116865296 hasConceptScore W2116865296C2776694085 @default.
• W2116865296 hasConceptScore W2116865296C2777847059 @default.
• W2116865296 hasConceptScore W2116865296C2778239845 @default.
• W2116865296 hasConceptScore W2116865296C2779013556 @default.

• next